Transasia Bio-Medicals acquires majority stakes in IVAX Diagnostics
Transasia Bio-Medicals, a leader in the Clinical Diagnostics Segment of the Indian healthcare sector through its fully owned German subsidiary, Erba Diagnostics Mannheim GmbH has acquired a majority stake in US based IVAX Diagnostics.
IVAX Diagnostics headquartered in Miami, Florida and listed on the NYSE Amex is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the US and internationally, proprietary diagnostic reagents, test kits and instrumentation, for Autoimmune and Infectious diseases, through its three subsidiaries: Diamedix Corporation (US), Delta Biologicals S.r.l. (Europe), and ImmunoVision (US) Transasia’s CMD, Suresh Vazirani has taken over as Executive Chairman of Ivax Diagnostics.
This comes within a year of Transasia’s acquisition in September 2009 of Erba Lachema s.r.o, a leading diagnostic company in Europe and Russia.
The synergy thus created will help Transasia to offer unique immunodiagnostic innovations in its products, procedures and in the development of Integrated Instrument and Reagent systems for both Autoimmune and Infectious Disease detection and will help IVAX to increase its reach in the Indian Market.
IVAX products which will be made available through Transasia include Autoimmune and Infectious Disease test kits as well as fully automated ELISA systems with simplified software, custom programmability, user-friendly set-up and operation, minimum hands-on time, and true ‘walk away’ capability. ImmunoVision – a member of the IVAX Diagnostics family is a leader in the autoimmune market.
The Product Portfolio is also expanded to include Immunoenzymatic and Immunoflourescence assays for Autoimmunity, Microbiology and Allergy panels.
This new basket of US FDA approved, wide spectrum, and progressive products from Transasia is definitely an added advantage which will benefit Indian customers due to high quality and affordable prices.